Published by
ValueWalk
ValueWalk
Britain has approved Thursday the Covid experimental oral treatment molnupiravir by Merck & Co (NYSE:MRK). This is the first approval of the antiviral drug around the world by a public health regulator, and experts agree this could be key to putting an end to the pandemic. Q3 2021 hedge fund letters, conferences and more Molnupiravir ApprovalAs reported by The Washington Post, should the drug be widely approved, it could have huge potential as, “pills are easier to take, manufacture and store, making them particularly useful in lower-to middle-income countries with weaker infrastructure and li…